Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway

Oncology Reports

Volumn 24, Issue 1, 2010, Pages 89-95

  Wen, Yu Gang ^a   Wang, Quan ^a   Zhou, Chong Zhi ^a   Qiu, Guo Qiang ^a   Peng, Zhi Hai ^a   Tang, Hua Mei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Gastric carcinoma; Gene mutation; PTEN; Tumor suppressor gene

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA; UVOMORULIN; ONCOPROTEIN; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CELL DIFFERENTIATION; CHINESE; CODON; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEGREGATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; STOMACH MUCOSA; TISSUE DIFFERENTIATION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; CARCINOMA; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; SIGNAL TRANSDUCTION; STOMACH TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 77952975814     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000832     Document Type: Article

References (39)

1. Fan D, Zhang X, Chen X, et al: Bird's-eye view on gastric cancer research of the past 25 years. J Gastroenterol Hepatol 20: 360-365, 2005. (Pubitemid 40469334)
2. Wu CX, Zheng Y, Bao PP, et al: Pattern of changing incidence of gastric cancer and its time trend in Shanghai. J Surg Concepts Pract 13: 24-29, 2008.
3. Wang X, Wu CX, Zheng Y and Wang JJ: Time trends and characteristics of gastric cancer incidence in urban Shanghai. Chin J Epidemiol 28: 875-880, 2007.
4. Lima EM, Araújo JJ, Harada ML, Assumpção PP, Burbano RR and Casartelli C: Molecular study of the tumour suppressor gene PTEN in gastric adenocarcinoma in Brazil. Clin Exp Med 5: 129-132, 2005.
5. Oki E, Kakeji Y, Baba H, et al: Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer. J Gastroenterol Hepatol 21: 814-818, 2006. (Pubitemid 43793276)
6. Groszer M, Erickson R, Adams DS, et al: Negative regulation of neural stem/progenitor cell proliferation by the PTEN tumor suppressor gene in vivo. Science 294: 2186-2189, 2001. (Pubitemid 33150679)
7. Stiles BL: Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENtacles. Int J Biochem Cell Biol 41: 757-761, 2009.
8. Raftopoulou M, Manneville SE, Self A, Nicholls S and Hall A: Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 303: 1179-1181, 2004. (Pubitemid 38233580)
9. Orrico A, Galli L, Buoni S, Orsi A, Vonella G and Sorrentino V: Novel PTEN mutations in neurodevelopmental disorders and macrocephaly. Clin Genet 75: 195-198, 2009.
10. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275: 1943-1947, 1997.
11. Bose K, Crane A, Hibshoosh H, Mansukhani M, Sandweis L and Parsons R: Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 33: 405-409, 2002. (Pubitemid 34627590)
12. Vranic S, Bilalovic N, Lee LM, Kruslin B, Lilleberg SL and Gatalica Z: PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney. Hum Pathol 38: 1425-1431, 2007. (Pubitemid 47247490)
13. Kolasa IK, Rembiszewska A, Jankowska AJ, Dansonka-Mieszkowska A, Lewandowska AM, Konopka B and Kupryjanczyk J: PTEN mutation, expression and LOH at its locus in ovarian carcinomas, Relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol 103: 692-697, 2006. (Pubitemid 44602189)
14. Tunca B, Bekar A, Cecener G, et al: Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme. J Neurooncol 82: 263-269, 2007. (Pubitemid 46614388)
15. Marsit CJ, Zheng SC, Aldape K, Hinds PW, Nelson HH, Wiencke JK and Kelsey KT: PTEN expression in non-small cell lung cancer: evaluating its relation to tumor characteristics, allelic loss and epigenetic alteration. Hum Pathol 36: 768-776, 2005. (Pubitemid 41112032)
16. Marty B, Maire V, Gravier E, et al: Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 10: R101, 2008.
17. Bansal N, Yendluri V and Wenham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification and targeted therapies. Cancer Control 16: 8-13, 2009.
18. Teng Y, Sun AN, Pan XC, Yang G, Yang LL, Wang MR and Yang X: Synergistic function of Smad4 and PTEN in suppressing forestomach squamous cell carcinoma in the mouse. Cancer Res 66: 6972-6981, 2006. (Pubitemid 44197672)
19. Perrone F, Lampis A, Orsenigo M, et al: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20: 84-90, 2009.
20. Danielsen SA, Lind GE, Bjørnslett M, Meling GI, Rognum TO, Heim S and Lothe RA: Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability and TP53 mutation status. Hum Mutat 29: 252-262, 2008.
21. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J and Li QL: Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 37: 389-396, 2007. (Pubitemid 46605424)
22. Japanese Research Society for Gastric Cancer: The general rules for the gastric cancer study. Part I. Clinical, surgical and conclusive findings. Part II. Histological findings. Kanehara Co., Tokyo, pp2-46, 1995.
23. Sambrook J, Fritsch EF and Maniatis T: Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, New York, pp622-634, 1989.
24. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP and Yin Y: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157-170, 2007. (Pubitemid 46048887)
25. Pezzolesi MG, Lim Y, Zhoum X-P, Pilarski R, Shen L and Eng C: Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes. Am J Hum Genet 79: 923-934, 2006. (Pubitemid 44763406)
26. Butler MG, Dasouki MJ, Zhou XP, Pastore M, Prior TW and Sommer A: Increasing knowledge of PTEN germline mutations: two additional patients with autism and macrocephaly. Am J Med Genet A 143: 589-593, 2007. (Pubitemid 46348901)
27. Wang JY, Huang TJ, Chen FM, Hsieh MC, Lin SR, Hou MF and Hsieh JS: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas. Virchows Arch 442: 437-443, 2003. (Pubitemid 36718310)
28. Fei G, Ebert MP, Mawrin C, Leodolter A, Schmidt N, Dietzmann K and Malfertheiner P: Reduced PTEN expression in gastric cancer and in the gastric mucosa of gastric cancer relatives. Eur J Gastroenterol Hepatol 14: 297-303, 2002. (Pubitemid 34259280)
29. Guo CY, Xu XF, Wu JY and Liu SF: PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer. World J Gastroenterol 14: 3804-3811, 2008.
30. Yu HG, Ai YW, Yu LL, et al: Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 122: 433-443, 2008.
31. Kang YH, Lee HS and Kim WH: Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 82: 285-291, 2002. (Pubitemid 34242522)
32. Hou P, Ji MJ and Xing MZ: Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/Akt signaling pathway in thyroid tumors. Cancer 113: 2440-2447, 2008.
33. Hwang PH, Kim SY, Lee JC, Kim SJ, Yi HK and Lee DY: PTEN/MMAC1 enhances the growth inhibition by anticancer drugs with down-regulation of IGF-II expression in gastric cancer cells. Exp Mol Med 37: 391-398, 2005.
34. McCubrey JA, Steelmana LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006.
35. Trotman LC, Wang X, Alimonti A, et al: Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128: 141-156, 2007. (Pubitemid 46048885)
36. Scheper MA, Chaisuparat R, Nikitakis NG and Sauk JJ: Expression and alterations of the PTEN/AKT/mTOR pathway in ameloblastomas. Oral Dis 14: 561-568, 2008.
37. Zheng HC, Takahashi H, Murai Y, Cui Z, Nomoto K, Tsuneyama K and Takano Y: Low expression of FHIT and PTEN correlates with malignancy of gastric carcinomas: tissue-array findings. Appl Immunohistochem Mol Morphol 15: 432-440, 2007. (Pubitemid 350307850)
38. Silva A, Yunes JA, Cardoso BA, et al: PTEN post-translational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118: 3762-3774, 2008.
39. Wee S, Wiederschain D, Maira SM, et al: PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 105: 13057-13062, 2008.